标题
Trial Watch: Monoclonal antibodies in cancer therapy
作者
关键词
-
出版物
OncoImmunology
Volume 1, Issue 1, Pages 28-37
出版商
Informa UK Limited
发表日期
2012-01-03
DOI
10.4161/onci.1.1.17938
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab®)
- (2012) Diane Seimetz Journal of Cancer
- Trials Define Anti-Tumor Effects of Anti-Resorptive Agents†
- (2011) Ben Weintraub BIODRUGS
- Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma
- (2011) Sally A. Hunsucker et al. BRITISH JOURNAL OF HAEMATOLOGY
- Modulation of tumor immunity by therapeutic monoclonal antibodies
- (2011) Riad Abès et al. CANCER AND METASTASIS REVIEWS
- Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
- (2011) Oliver Kepp et al. CANCER AND METASTASIS REVIEWS
- Preclinical Evaluation of 177Lu-Nimotuzumab: A Potential Tool for Radioimmunotherapy of Epidermal Growth Factor Receptor–Overexpressing Tumors
- (2011) Denis Rolando Beckford Vera et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
- (2011) Nicholas S. Wilson et al. CANCER CELL
- Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
- (2011) Dirk Nagorsen et al. EXPERIMENTAL CELL RESEARCH
- Enhanced antibody-dependent cellular phagocytosis by chimeric monoclonal antibodies with tandemly repeated Fc domains
- (2011) Hiroaki Nagashima et al. JOURNAL OF BIOSCIENCE AND BIOENGINEERING
- CD30: an important new target in hematologic malignancies
- (2011) Yehuda E. Deutsch et al. LEUKEMIA & LYMPHOMA
- JAK1 Activates STAT3 Activity in Non-Small-Cell Lung Cancer Cells and IL-6 Neutralizing Antibodies Can Suppress JAK1-STAT3 Signaling
- (2011) L. Song et al. MOLECULAR CANCER THERAPEUTICS
- Exploring the vaccine potential of Dec-205 targeting in Mycobacterium tuberculosis infection in mice
- (2011) Elena Stylianou et al. VACCINE
- Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies
- (2010) H. M. Horton et al. BLOOD
- Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
- (2010) R. Abes et al. BLOOD
- A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
- (2010) J-F Rossi et al. BRITISH JOURNAL OF CANCER
- Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
- (2010) Brian I. Rini et al. CANCER
- Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor α
- (2010) Gaurav D. Shah et al. CANCER
- Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma
- (2010) Angel Casaco et al. CANCER BIOLOGY & THERAPY
- Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)
- (2010) Andres Forero-Torres et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
- (2010) SaeGwang Park et al. CANCER CELL
- Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors
- (2010) T. Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase II Trial of Docetaxel With Bevacizumab as First-line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01)
- (2010) Sara A. Hurvitz et al. Clinical Breast Cancer
- Targeting the Receptor for Platelet-Derived Growth Factor as a Primary or Combination Therapy in a Preclinical Model of Prostate Cancer Skeletal Metastasis
- (2010) M. R. Russell et al. CLINICAL CANCER RESEARCH
- A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies
- (2010) B. Kuenen et al. CLINICAL CANCER RESEARCH
- Novel Bone-Targeted Strategies in Oncology
- (2010) S. Vallet et al. CLINICAL CANCER RESEARCH
- A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
- (2010) R. S. Herbst et al. CLINICAL CANCER RESEARCH
- Pharmacokinetic and Pharmacodynamic Modeling of an Anti-Interleukin-6 Chimeric Monoclonal Antibody (Siltuximab) in Patients with Metastatic Renal Cell Carcinoma
- (2010) T. Puchalski et al. CLINICAL CANCER RESEARCH
- Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
- (2010) T. B. Dorff et al. CLINICAL CANCER RESEARCH
- Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague
- (2010) Yoonkyung Do et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells
- (2010) Stephen M Ansell EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Molecular mechanisms of the antitumor effects of anti-CD20 antibodies
- (2010) Magdalena Winiarska Frontiers in Bioscience-Landmark
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease
- (2010) Frits van Rhee et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Pretargeted 177Lu Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colonic Tumors in Mice
- (2010) R. Schoffelen et al. JOURNAL OF NUCLEAR MEDICINE
- Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
- (2010) Gregory L. Moore et al. mAbs
- A Combination of DR5 Agonistic Monoclonal Antibody with Gemcitabine Targets Pancreatic Cancer Stem Cells and Results in Long-term Disease Control in Human Pancreatic Cancer Model
- (2010) N. V. Rajeshkumar et al. MOLECULAR CANCER THERAPEUTICS
- Ofatumumab
- (2010) Michael J. Keating et al. NATURE REVIEWS DRUG DISCOVERY
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy
- (2010) Robert M. Sharkey et al. SEMINARS IN NUCLEAR MEDICINE
- Clinical Studies With Anti–CTLA-4 Antibodies in Non-melanoma Indications
- (2010) Luana Calabrò et al. SEMINARS IN ONCOLOGY
- Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor
- (2009) Jerry Y. Hsu et al. BIODRUGS
- 131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma
- (2009) A. K. Gopal et al. BLOOD
- Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death
- (2009) Peter M. Voorhees et al. BRITISH JOURNAL OF HAEMATOLOGY
- Complement and its role in innate and adaptive immune responses
- (2009) Jason R Dunkelberger et al. CELL RESEARCH
- Cixutumumab
- (2009) Kevin P McKian et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
- (2009) Cornelia Haas et al. IMMUNOBIOLOGY
- PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells
- (2009) Wenshi Wang et al. INTERNATIONAL IMMUNOLOGY
- Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1
- (2009) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
- (2009) Luis H. Camacho et al. JOURNAL OF CLINICAL ONCOLOGY
- AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells
- (2009) P. J. Beltran et al. MOLECULAR CANCER THERAPEUTICS
- Glycosylation as a strategy to improve antibody-based therapeutics
- (2009) Roy Jefferis NATURE REVIEWS DRUG DISCOVERY
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
- (2009) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
- A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes
- (2008) A. Yada et al. ANNALS OF ONCOLOGY
- Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
- (2008) Y Akashi et al. BRITISH JOURNAL OF CANCER
- Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16
- (2008) Christophe de Romeuf et al. BRITISH JOURNAL OF HAEMATOLOGY
- FcγRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients
- (2008) Márcia Paiva et al. CANCER GENETICS AND CYTOGENETICS
- Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
- (2008) A. Natsume et al. CANCER RESEARCH
- Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
- (2008) G Kroemer et al. CELL DEATH AND DIFFERENTIATION
- Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies
- (2008) L. M. Weiner et al. CLINICAL CANCER RESEARCH
- Targeting TRAIL death receptors
- (2008) CNAM Oldenhuis et al. CURRENT OPINION IN PHARMACOLOGY
- Selective expression of inhibitory Fcγ receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response
- (2008) Lydie Cassard et al. INTERNATIONAL JOURNAL OF CANCER
- Antibody association with HER-2/neu–targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs
- (2008) Peter S. Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin
- (2008) David Sancho et al. JOURNAL OF CLINICAL INVESTIGATION
- Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response
- (2008) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search